Our Services
Medical Information
Helpful Resources
Published on: 2/28/2026
If Humira is not working, there are several factors to consider, including primary non-response or secondary loss of response from anti-drug antibodies, low drug levels, disease changes, or missed doses.
Medically approved next steps include confirming the diagnosis, checking adalimumab trough and antibody levels, adjusting dose or adding methotrexate, and switching to another TNF inhibitor or to a different class such as IL-6, IL-12/23, IL-17, integrin, B cell, T cell costimulation, or JAK therapies. See the complete, important details below, including when symptoms are urgent and typical time frames to judge response, to help you choose the safest next step with your clinician.
If Humira isn't working the way you hoped, you're not alone. Many people taking Humira (adalimumab) for conditions like rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and others eventually notice reduced benefits—or no improvement at all.
The good news? There are medically proven next steps. Treatment failure does not mean you're out of options. Let's walk through what might be happening and what science-backed strategies doctors use next.
Humira is a biologic medication known as a TNF inhibitor. It works by blocking tumor necrosis factor-alpha (TNF-α), a substance in your body that causes inflammation.
In autoimmune diseases, your immune system mistakenly attacks healthy tissue. TNF plays a key role in driving that inflammation. By blocking TNF, Humira helps:
But not everyone responds the same way.
There are two main patterns doctors see:
This means Humira never worked well from the beginning.
Possible reasons:
This means Humira worked at first, but then stopped working.
This is common and often happens because:
If symptoms are returning or worsening, it's important not to assume the medication has completely failed without proper evaluation.
Depending on your condition, signs may include:
If you're experiencing persistent symptoms and want to better understand whether they might be related to Rheumatoid Arthritis (RA), a free AI-powered symptom checker can help you organize your concerns and prepare meaningful questions before your next doctor's appointment.
If Humira isn't working, doctors don't simply "wait and see." There are structured, evidence-based strategies.
Sometimes symptoms persist because:
Your doctor may order:
For some conditions (especially IBD and RA), doctors can measure:
This helps determine whether:
This approach is called therapeutic drug monitoring, and it's increasingly used in modern rheumatology and gastroenterology.
In some cases, doctors may:
This is more common in inflammatory bowel disease than in RA, but it depends on your situation.
Combination therapy can sometimes restore effectiveness.
For rheumatoid arthritis, doctors may add:
Methotrexate in particular may reduce the formation of antibodies against Humira.
If Humira stops working, switching to another TNF blocker may help.
Examples include:
Some patients respond well to a different TNF inhibitor even if one fails.
If TNF is not the main driver of your inflammation, your doctor may recommend a biologic with a different target.
For RA, options include:
For IBD or psoriasis:
Modern treatment guidelines support switching classes if TNF inhibitors fail.
While most Humira issues are not emergencies, seek immediate medical care if you experience:
Because Humira suppresses part of the immune system, infections can become serious more quickly. Always speak to a doctor right away about potentially life-threatening symptoms.
Medication works best when supported by healthy habits. Evidence suggests that response to biologics may improve with:
Obesity, in particular, has been associated with reduced response to TNF inhibitors in some studies.
This depends on your condition, but generally:
Doctors use formal scoring systems to measure improvement. If there's inadequate response after the expected time frame, treatment changes are typically recommended.
Sometimes, yes—especially if the issue was low drug levels or missed doses. But if your body has developed significant anti-drug antibodies, switching therapies is often more effective.
When Humira stops working, it can feel discouraging. Many patients worry:
It's important to know that treatment options for autoimmune diseases have expanded dramatically in the past decade. There are more FDA-approved therapies now than ever before. A medication failing does not mean your condition is untreatable.
If you're uncertain whether your symptoms indicate worsening disease, using a free Rheumatoid Arthritis (RA) symptom assessment tool can help you document what you're experiencing and have a more productive conversation with your healthcare provider.
If Humira isn't working, there is a clear, medically supported pathway forward:
Treatment resistance is common—and manageable. The key is not to ignore persistent symptoms.
Most importantly, speak to a doctor about any worsening symptoms, severe pain, signs of infection, or anything that could be serious or life threatening. Your healthcare provider can guide you through the next best step safely and effectively.
You have options. And with modern therapies, many patients do find a treatment that works.
(References)
* Smolen JS, van der Heijde D, Koenders M, St Clair EW, Emery P, Bathon JM, van Vollenhoven R, Strand V, Vencovsky J, Ritschl V. Management of immunogenicity to biologics in rheumatoid arthritis: treatment switching or optimization? RMD Open. 2021 Jul;7(2):e001716. doi: 10.1136/rmdopen-2021-001716. PMID: 34326127; PMCID: PMC8322695.
* Baillie T, Khan F, Cheema M, Walmsley M, Mahida YR. Treatment optimization strategies in inflammatory bowel disease: When to adjust, when to switch, and when to combine. J Gastroenterol Hepatol. 2021 Dec;36(12):3313-3323. doi: 10.1111/jgh.15655. PMID: 34520556.
* Billiet T, Papamichael K, Ferrante M. Therapeutic drug monitoring of adalimumab in inflammatory bowel disease: an update. Expert Rev Gastroenterol Hepatol. 2022 Mar;16(3):233-242. doi: 10.1080/17476309.2022.2036729. PMID: 35105268.
* Papamichael K, Jairath V, Tilg H, Cheifetz AS. Immunogenicity and therapeutic drug monitoring of anti-TNF-α agents in immune-mediated inflammatory diseases: a systematic review. J Autoimmun. 2017 May;79:1-12. doi: 10.1016/j.jaut.2017.02.007. Epub 2017 Feb 23. PMID: 28238716.
* Yarur AJ, Salgado M, Czul F, Ghazi L, Deshpande AR, Peerani F, Abreu MT. Optimizing Adalimumab Treatment in Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2015 Oct 8;6(10):e115. doi: 10.1038/ctg.2015.42. PMID: 26447814; PMCID: PMC4716298.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.